BIOMAT Database Logo BIOMAT Database Logo

[Reaferon and interferonogenes in the therapy of acute viral hepatitis B]. 1991

M A Andreĭchin, and A V Zmyzgova, and A S Rudchik

Monotherapy with reaferon (alpha 2-interferon) versus prodigiosan plus ibuprofen combination was investigated in acute viral hepatitis B. The drugs were found to stimulate cellular immunity and to induce a decrease of total serum IgE levels. The effect of prodigiosan combined with ibuprofen proved more pronounced.

UI MeSH Term Description Entries
D007052 Ibuprofen A non-steroidal anti-inflammatory agent with analgesic, antipyretic, and anti-inflammatory properties Advil,Benzeneacetic Acid, alpha-methyl-4-(2-methylpropyl)- trimethylsilyl ester,Brufen,Ibumetin,Ibuprofen, (+-)-Isomer,Ibuprofen, (R)-Isomer,Ibuprofen, (S)-Isomer,Ibuprofen, Aluminum Salt,Ibuprofen, Calcium Salt,Ibuprofen, Copper (2+) Salt,Ibuprofen, Magnesium Salt,Ibuprofen, Potassium Salt,Ibuprofen, Sodium Salt,Ibuprofen, Zinc Salt,Ibuprofen-Zinc,Motrin,Nuprin,Rufen,Salprofen,Trauma-Dolgit Gel,alpha-Methyl-4-(2-methylpropyl)benzeneacetic Acid,Ibuprofen Zinc,Trauma Dolgit Gel
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011354 Prodigiozan A polysaccharide extracted from Serratia marcescens and other bacteria. It activates enzymatic activity of macrophages and stimulates phagocytic processes. Prodigiosan
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
[Use of interferon inducers and reaferon in the combined therapy of acute viral hepatitis B].
January 1988, Terapevticheskii arkhiv,
M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
[Reaferon treatment in acute HBsAG-positive viral hepatitis].
March 1990, Klinicheskaia meditsina,
M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
[The reaferon treatment of a patient with acute viral hepatitis B and hemorrhagic vasculitis].
October 1990, Vrachebnoe delo,
M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
[Approaches to perfection of Reaferon therapy in hepatitis B].
January 1996, Klinicheskaia meditsina,
M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
[Prophylactic efficacy of reaferon in viral hepatitis A and acute respiratory infections in children].
May 1988, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
[The effect of recombinant alfa-2 interferon (reaferon) on the functional activity of natural killers in acute viral hepatitis B].
January 1995, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
[Comparative results of therapy with amizon and reaferon of patients with chronic viral hepatitis B and C and kidney complications].
January 2003, Likars'ka sprava,
M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
Serum hepatitis B viral DNA in acute viral hepatitis B.
June 1989, Annals of internal medicine,
M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
[The use of reaferon in treating patients with protracted viral hepatitis].
January 1994, Terapevticheskii arkhiv,
M A Andreĭchin, and A V Zmyzgova, and A S Rudchik
Antiviral therapy in acute viral hepatitis B: why and when.
January 2009, Infectious agents and cancer,
Copied contents to your clipboard!